• Je něco špatně v tomto záznamu ?

Antisense Therapy for a Common Corneal Dystrophy Ameliorates TCF4 Repeat Expansion-Mediated Toxicity

C. Zarouchlioti, B. Sanchez-Pintado, NJ. Hafford Tear, P. Klein, P. Liskova, K. Dulla, M. Semo, AA. Vugler, K. Muthusamy, L. Dudakova, HJ. Levis, P. Skalicka, P. Hysi, ME. Cheetham, SJ. Tuft, P. Adamson, AJ. Hardcastle, AE. Davidson,

. 2018 ; 102 (4) : 528-539. [pub] 20180308

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000880
E-zdroje Online Plný text

NLK Cell Press Free Archives od 1997-01-01 do Před 6 měsíci
Free Medical Journals od 1949 do Před 6 měsíci
PubMed Central od 1949 do Před 6 měsíci
Europe PubMed Central od 1949 do Před 6 měsíci
Open Access Digital Library od 2005-01-01

Odkazy

PubMed 29526280
DOI 10.1016/j.ajhg.2018.02.010
Knihovny.cz E-zdroje

Fuchs endothelial corneal dystrophy (FECD) is a common disease for which corneal transplantation is the only treatment option in advanced stages, and alternative treatment strategies are urgently required. Expansion (≥50 copies) of a non-coding trinucleotide repeat in TCF4 confers >76-fold risk for FECD in our large cohort of affected individuals. An FECD subject-derived corneal endothelial cell (CEC) model was developed to probe disease mechanism and investigate therapeutic approaches. The CEC model demonstrated that the repeat expansion leads to nuclear RNA foci, with the sequestration of splicing factor proteins (MBNL1 and MBNL2) to the foci and altered mRNA processing. Antisense oligonucleotide (ASO) treatment led to a significant reduction in the incidence of nuclear foci, MBNL1 recruitment to the foci, and downstream aberrant splicing events, suggesting functional rescue. This proof-of-concept study highlights the potential of a targeted ASO therapy to treat the accessible and tractable corneal tissue affected by this repeat expansion-mediated disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000880
003      
CZ-PrNML
005      
20190110101947.0
007      
ta
008      
190107s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ajhg.2018.02.010 $2 doi
035    __
$a (PubMed)29526280
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zarouchlioti, Christina $u UCL Institute of Ophthalmology, London ECIV 9EL, UK.
245    10
$a Antisense Therapy for a Common Corneal Dystrophy Ameliorates TCF4 Repeat Expansion-Mediated Toxicity / $c C. Zarouchlioti, B. Sanchez-Pintado, NJ. Hafford Tear, P. Klein, P. Liskova, K. Dulla, M. Semo, AA. Vugler, K. Muthusamy, L. Dudakova, HJ. Levis, P. Skalicka, P. Hysi, ME. Cheetham, SJ. Tuft, P. Adamson, AJ. Hardcastle, AE. Davidson,
520    9_
$a Fuchs endothelial corneal dystrophy (FECD) is a common disease for which corneal transplantation is the only treatment option in advanced stages, and alternative treatment strategies are urgently required. Expansion (≥50 copies) of a non-coding trinucleotide repeat in TCF4 confers >76-fold risk for FECD in our large cohort of affected individuals. An FECD subject-derived corneal endothelial cell (CEC) model was developed to probe disease mechanism and investigate therapeutic approaches. The CEC model demonstrated that the repeat expansion leads to nuclear RNA foci, with the sequestration of splicing factor proteins (MBNL1 and MBNL2) to the foci and altered mRNA processing. Antisense oligonucleotide (ASO) treatment led to a significant reduction in the incidence of nuclear foci, MBNL1 recruitment to the foci, and downstream aberrant splicing events, suggesting functional rescue. This proof-of-concept study highlights the potential of a targeted ASO therapy to treat the accessible and tractable corneal tissue affected by this repeat expansion-mediated disease.
650    _2
$a senioři $7 D000368
650    _2
$a zvířata $7 D000818
650    _2
$a buněčné jádro $x účinky léků $x metabolismus $7 D002467
650    _2
$a kohortové studie $7 D015331
650    _2
$a endoteliální buňky $x metabolismus $7 D042783
650    _2
$a rohovkový endotel $x patologie $7 D004728
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a Fuchsova endoteliální dystrofie $x genetika $x patologie $7 D005642
650    12
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a antisense oligonukleotidy $x farmakologie $7 D016376
650    _2
$a orgánová specificita $7 D009928
650    _2
$a prekurzory RNA $x genetika $7 D012322
650    _2
$a posttranskripční úpravy RNA $7 D012323
650    _2
$a sestřihové faktory $x metabolismus $7 D000072260
650    _2
$a messenger RNA $x metabolismus $7 D012333
650    _2
$a rizikové faktory $7 D012307
650    _2
$a transkripční faktor 4 $x genetika $7 D000073940
650    _2
$a expanze trinukleotidových repetic $x genetika $7 D019680
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sanchez-Pintado, Beatriz $u UCL Institute of Ophthalmology, London ECIV 9EL, UK.
700    1_
$a Hafford Tear, Nathaniel J $u UCL Institute of Ophthalmology, London ECIV 9EL, UK.
700    1_
$a Klein, Pontus $u ProQR Therapeutics, Zernikedreef 9, 2333 CK Leiden, the Netherlands.
700    1_
$a Liskova, Petra $u Research Unit for Rare Diseases, Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic; Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague, Czech Republic.
700    1_
$a Dulla, Kalyan $u ProQR Therapeutics, Zernikedreef 9, 2333 CK Leiden, the Netherlands.
700    1_
$a Semo, Ma'ayan $u UCL Institute of Ophthalmology, London ECIV 9EL, UK.
700    1_
$a Vugler, Anthony A $u UCL Institute of Ophthalmology, London ECIV 9EL, UK.
700    1_
$a Muthusamy, Kirithika $u UCL Institute of Ophthalmology, London ECIV 9EL, UK; Moorfields Eye Hospital, London EC1V 2PD, UK.
700    1_
$a Dudakova, Lubica $u Research Unit for Rare Diseases, Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic.
700    1_
$a Levis, Hannah J $u Institute of Aging and Chronic Disease, University of Liverpool, Liverpool L7 8TX, UK.
700    1_
$a Skalicka, Pavlina $u Research Unit for Rare Diseases, Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic; Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague, Czech Republic.
700    1_
$a Hysi, Pirro $u Department of Ophthalmology and Twin Research, King's College London, London SE1 7EH, UK.
700    1_
$a Cheetham, Michael E $u UCL Institute of Ophthalmology, London ECIV 9EL, UK.
700    1_
$a Tuft, Stephen J $u UCL Institute of Ophthalmology, London ECIV 9EL, UK; Moorfields Eye Hospital, London EC1V 2PD, UK.
700    1_
$a Adamson, Peter $u ProQR Therapeutics, Zernikedreef 9, 2333 CK Leiden, the Netherlands.
700    1_
$a Hardcastle, Alison J $u UCL Institute of Ophthalmology, London ECIV 9EL, UK.
700    1_
$a Davidson, Alice E $u UCL Institute of Ophthalmology, London ECIV 9EL, UK. Electronic address: alice.davidson@ucl.ac.uk.
773    0_
$w MED00000254 $t American journal of human genetics $x 1537-6605 $g Roč. 102, č. 4 (2018), s. 528-539
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29526280 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190110102151 $b ABA008
999    __
$a ok $b bmc $g 1363942 $s 1039003
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 102 $c 4 $d 528-539 $e 20180308 $i 1537-6605 $m American journal of human genetics $n Am J Hum Genet $x MED00000254
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace